REGEnLIFE is an advanced clinical-stage medical technology company focused on treating neurological conditions. Nearing market launch, it is developing a pioneering, patented therapeutic solution based on biophotonics. This non-invasive and painless application for patients takes the form of a helmet and an abdominal belt to target the brain and/or gut, depending on the pathology. Indeed, recent scientific studies suggest the key role of the brain-gut axis in the development of neurological conditions.
REGEnLIFE is able to make its devices available for clinical and preclinical research, and is preparing to market a product dedicated to the treatment of concussions.
RGn600: an innovative non-invasive medical device using brain and gut stimulation via photobiomodulation.
REGEnLIFE markets the RGn600 for research purposes, the first medical device targeting the brain and gut to treat neuroinflammation.
REGEnBRAIN: a non-invasive medical device for the treatment of concussions.
REGEnLIFE is preparing to commercialize REGEnBRAIN for acute concussion indication.
Neurotechnology Research and Development
Innovative medical devices for Alzheimer’s disease and other neurological conditions.
REGEnLIFE is an innovative company based in Montpellier.
